Clinical Trial

Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 23, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and initial efficacy of CM313 (SC) injection in patients with primary immune thrombocytopenia.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-10; most recent amendment 2025-04-18.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-04-18
Trial Details
NCT Number NCT06594146
Lead Sponsor Keymed Biosciences Co.Ltd
Conditions Primary Immune Thrombocytopenia
Enrollment 62 participants
Start Date 2024-11-11
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-23